Silencing IGFBP-2 expression reduces the resistance to docetaxel in prostate cancer cells [18] and results in significant sensitization to cisplatin in esophageal adenocarcinoma cells [15]. This evidence concerns the gene IGFBP2 and esophageal adenocarcinoma.